Furthermore, inhibition of PARP1 by low doses of two inhibitors, DPQ and olaparib, blocks activation of TSPs and cancer-related genes in hepatoblastoma cell lines, HepG2, Huh6, and B6-2, which facilitates the development of clinical trials for patients with aggressive HBL. Here, PARP1 is linked to cancer.